Impact of Routine Quantiferon Testing on Latent Tuberculosis Diagnosis and Treatment in Refugees in Multnomah County, Oregon, November 2009–October 2012

Journal of Immigrant and Minority Health

Volumn 18, Issue 2, 2016, Pages 292-300

  Walters, Jaime K ^a   Sullivan, Amy D ^a  

^a MULTNOMAH COUNTY HEALTH DEPARTMENT   (United States)

Author keywords

Diagnosis; Latent tuberculosis; Refugee; Treatment completion; Treatment initiation; Tuberculosis

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; COHORT ANALYSIS; COMMUNICABLE DISEASE CONTROL; FEMALE; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OREGON; ORGANIZATION AND MANAGEMENT; PILOT STUDY; PREVALENCE; PROCEDURES; PUBLIC HEALTH; REFUGEE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX RATIO; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; COHORT STUDIES; COMMUNICABLE DISEASE CONTROL; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; LOGISTIC MODELS; MALE; MASS SCREENING; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OREGON; PILOT PROJECTS; PREVALENCE; PUBLIC HEALTH; REFUGEES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; YOUNG ADULT;

EID: 84925070841     PISSN: 15571912     EISSN: 15571920     Source Type: Journal    
DOI: 10.1007/s10903-015-0187-z     Document Type: Article

References (28)

1. Alami NN, Yuen CM, Miramontes R, Pratt R, Price SF, Navin TR, et al. Trends in tuberculosis—United States, 2013. MMWR Morb Mortal Wkly Rep. 2014;63(11):229–33.
2. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161(4 Pt 2):S221–47.
3. Bennett RJ, Brodine S, Waalen J, Moser K, Rodwell TC. Prevalence and treatment of latent tuberculosis infection among newly arrived refugees in San Diego County, January 2010–October 2012. Am J Public Health. 2014;104(4):e95–102.
4. Cain KP, Haley CA, Armstrong LR, Garman KN, Wells CD, Iademarco MF, et al. Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. Am J Respir Crit Care Med. 2007;175(1):75–9.
5. Horsburgh CR, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med. 2011;364(15):1441–8.
6. Geng E, Kreiswirth B, Driver C, Li J, Burzynski J, DellaLatta P, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med. 2002;346(19):1453–8.
7. Ricks PM, Cain KP, Oeltmann JE, Kammerer JS, Moonan PK. Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the US, 2005–2009. PLoS One. 2011;6(11):e27405.
8. Hadzibegovic DS, Maloney SA, Cookson ST, Oladele A. Determining TB rates and TB case burden for refugees. Int J Tuberc Lung Dis. 2005;9(4):409–14.
9. Varkey P, Jerath AU, Bagniewski SM, Lesnick TG. The epidemiology of tuberculosis among primary refugee arrivals in Minnesota between 1997 and 2001. J Travel Med. 2007;14(1):1–8.
10. Taylor Z, Nolan CM, Blumberg HM, American Thoracic Society, Centers for Disease Control and Prevention, et al. Controlling tuberculosis in the United States Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep Cent Dis Control. 2005;54(RR-12):1–81.
11. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep Cent Dis Control. 2010;59(Rr-5):1–25.
12. Cellestis. Quantiferon-TB Gold (in-tube method) package insert. 2006. http://www.cellestis.com/IRM/Company/ShowPage.aspx?CPID=1171. Accessed 01 Dec 2014.
13. World Health Organization. Global tuberculosis report 2013. Geneva. 2013. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf?ua=1. Accessed 28 Aug 2014.
14. Drobniewski F, Balabanova Y, Zakamova E, Nikolayevskyy V, Fedorin I. Rates of latent tuberculosis in health care staff in Russia. PLoS Med. 2007;4(2):e55.
15. Shah M, DiPietro D, Greenbaum A, Ketemepi S, Martins-Evora M, Marsiglia V, et al. Programmatic impact of QuantiFERON-TB gold in-tube implementation on latent tuberculosis diagnosis and treatment in a public health clinic. PLoS One. 2012;7(5):e36551.
16. Levesque JF, Dongier P, Brassard P, Allard R. Acceptance of screening and completion of treatment for latent tuberculosis infection among refugee claimants in Canada. Int J Tuberc Lung Dis. 2004;8(6):711–7.
17. Trauer JM, Krause VL. Assessment and management of latent tuberculosis infection in a refugee population in the Northern Territory. Med J Aust. 2011;194(11):579–82.
18. Nuzzo JB, Golub JE, Chaulk P, Shah M. Analysis of latent tuberculosis infection treatment adherence among refugees and other patient groups referred to the Baltimore City Health Department TB Clinic, February 2009–March 2011. J Immigr Minor Health. 2015;17(1):56–65.
19. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008;12(11):1235–54.
20. Butcher K, Biggs BA, Leder K, Lemoh C, O’Brien D, Marshall C. Understanding of latent tuberculosis, its treatment and treatment side effects in immigrant and refugee patients. BMC Res Notes. 2013;6:342.
21. Abraham BK, Winston CA, Magee E, Miramontes R. Tuberculosis among Africans living in the United States, 2000–2009. J Immigr Minor Health. 2013;15(2):381–9.
22. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest. 2006;130(6):1712–7.
23. Li J, Munsiff SS, Tarantino T, Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis. 2010;14(4):e292–7.
24. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170(4):445–9.
25. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166(17):1863–70.
26. Centers for Disease Control, Prevention. Impact of a shortage of first-line antituberculosis medication on tuberculosis control—United States, 2012–2013. MMWR Morb Mortal Wkly Rep. 2013;62(20):398–400.
27. Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis. 2010;14(5):551–9.
28. Centers for Disease and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60(48):1650–3.